Idenix Pharmaceuticals, Inc. leads Friday small-cap pre-market volume
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) said the FDA has essentially rejected its hepatitis C drug. Idenix is “not optimistic” about the drug’s future prospects, CEO Jean-Pierre Sommadossi said.
The following are the most actively traded companies in Friday pre-market trading among those with market capitalizations under $500 million:
| Price at | % | ||||||
| 9:17 et | Change | Change | Volume | Year High | Year Low |
